UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

Flamel Technologies, S.A.

(Translation of registrant’s name into English)

Parc Club du Moulin à Vent
33 avenue du Dr. Georges Levy
69693 Vénissieux Cedex France
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F þ Form 40-F o

Indicate by check mark whether registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No þ

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-                    

 

 

INFORMATION FILED WITH THIS REPORT

Document Index

99.1

Press Release dated June 3, 2008

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Exhibit 99.1

For Immediate Release

Flamel Technologies Announces Results of Annual Meeting

Lyon, France — June 3, 2008 — Flamel Technologies S.A. (NASDAQ: FLML) today announced the results of its annual meeting held on June 3, 2008. The election of each member of the Board of Directors of the Company for a further one-year term was approved by holders of more than 98% of the Company’s shares. Each additional resolution proposed favorably by management at the meeting was approved by holders of more than 93% of the Company’s shares.

As a consequence, shareholders re-elected Flamel’s Board of Directors. Mr. Elie Vannier, the Senior Advisor and Operating Partner at Oaktree Capital Management, will continue to serve as the Company’s non-Executive Chairman. Also re-elected to the Company’s Board of Directors were: Mr. Lodewijk J.R. deVink, former Chairman and Chief Executive Officer of Warner Lambert; Dr. Frank Fildes, PhD., former Senior Vice President: Head of Global Drug Development of Astra Zeneca PLC; Mr. Frederic Lemoine, Chairman of the Supervisory Board of AREVA, Mr. John Vogelstein, former President of Warburg Pincus; and Mr. Stephen H. Willard, Flamel’s Chief Executive Officer.

“We are pleased to have the strong support of our shareholders,” said Mr. Elie Vannier, non-Executive Chairman of Flamel. “As a result of the progress made by our teams under the leadership of Stephen Willard and Rafael Jorda, Flamel has achieved some important successes over the past year which have served to strengthen the Medusa platform. As a result, the Company has signed important agreements with Merck Serono and Wyeth and has another eight Medusa feasibility studies in development with other partners. These relationships, together with the good relationship that the Company enjoys with GlaxoSmithKline for Coreg CR, as well as other Micropump ongoing programs, including TriggerLock®, serve as a strong foundation for the Company’s growth going forward.”

The Company has 24,066,600 shares issued or outstanding. Votes representing 24,011,961 shares, or 99.8% were tendered.

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel’s Medusa technology is designed to deliver controlled-release formulations of therapeutic proteins.

Contacts:

Charles Marlio, Director of Strategic Planning and Investor Relations
Tel: (011) 33-4-7278-3434
Fax: (011) 33-4-7278-3435
Marlio@flamel.com

This document contains a number of matters, particularly as related to financial projections and the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.

These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel’s reliance on outside parties and key strategic alliances.

These and other risks are described more fully in Flamel’s Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2007.

Coreg-CR is a registered trademark of GlaxoSmithKline.